Skip to main content
Clinical Trials/TCTR20190227003
TCTR20190227003
Not yet recruiting
Not Applicable

A study of incidence of molecular mutations in newly diagnosed acute myeloid leukemia (AML) patients by Next-generation sequencing technique

The organization takes responsibility for initiating a study.0 sites139 target enrollmentFebruary 27, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
ewly diagnosed acute myeloid leukemia aged greater than 18 years
Sponsor
The organization takes responsibility for initiating a study.
Enrollment
139
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 27, 2019
End Date
March 1, 2020
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
The organization takes responsibility for initiating a study.

Eligibility Criteria

Inclusion Criteria

  • Thai newly diagnosed AML patients aged greater than 18 years who signed consent in Protocol title The newly diagnosed acute myeloid leukemia registry and ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sample collections for further investigating about molecular mutations: Protocol number 793/2560(EC2\) and had extracted DNA and RNA samples

Exclusion Criteria

  • 1\. A patient who has poor extracted DNA quality

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
A study of the incidence of molecular mutations in newly diagnosed acute lymphoblastic leukemia (ALL) patients by Next-generation sequencing techniqueThai newly diagnosed ALL patients aged greater than 18 years.Acute lymphoblastic leukemia, Next-generation sequencing ,Molecular mutations
TCTR20240409003Siriraj Hospital Mahidol University140
Active, not recruiting
Not Applicable
A study to assess the incidence in the UK of a change in a protein found in patients with newly diagnosed non-small cell lung cancer which has advanced or spread, and to investigate the quality of life of these patients when they receive treatment with erlotinib (Tarceva®) alone as a first treatment for this stage of their disease.
EUCTR2010-021120-96-GBRoche Products Limited1,200
Not yet recruiting
Not Applicable
Profile of genetic mutation and variation in early-onset Parkinson’s disease patient in ThailandGenetic mutation in early&#45onset Parkinson&#39s disease patient in Thailandearly&#45onset Parkinson’s diseasegenetic mutationnext generation sequencing
TCTR20180316002Faculty of Medicine, Chulalongkorn University51
Recruiting
Phase 1
Study on the correlation between gene mutation and TCM syndrome types in metastatic colorectal cancerMetastatic colorectal cancer
ITMCTR2100004411onghua Hospital Affiliated to Shanghai University of traditional Chinese Medicine
Unknown
Not Applicable
The investiaton of comprehenve genetic mutation in patients with HCC and hepatitis.HCC/hepatitis
JPRN-UMIN000024590Chiba university50